Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Etanercept in Children and Adolescents With Extended Oligoarticular Juvenile Idiopathic Arthritis, Enthesitis-Related Arthritis, or Psoriatic Arthritis
2009-012520-84Phase 3Completed
- Sponsor
- Wyeth
- Start
- Jul 2009
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of etanercept in juvenile idiopathic arthritis (JIA), juvenile idiopathic arthritis, enthesitis-related (JIA-ERA) and psoriatic arthritis (PsA), sponsored by Wyeth. Primary endpoints: Clinical benefit in combined population and Safety and physical functioning. Started Jul 2009; status: completed.
02
Drugs
etanercept
03
Conditions
juvenile idiopathic arthritis (JIA)juvenile idiopathic arthritis, enthesitis-related (JIA-ERA)psoriatic arthritis (PsA)
Beyond the preview
Go deeper on 2009-012520-84.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-012520-84.